Illustrative image — not a photograph of study participants or study data.What happened?
Navepegritide is a prodrug containing C-type natriuretic peptide (CNP). CNP released from the medicine binds to the NPR-B receptor and promotes processes in cartilage cells that stimulate bone growth. In a randomized, double-blind, placebo-controlled 52-week trial, annualised growth velocity improved by 1.49 cm compared with placebo. The European Commission must still make the final authorisation decision.